Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Hypoxia01:23

Hypoxia

Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is rectal preparation necessary in contemporary image-guided prostate radiotherapy?

Clinical and translational radiation oncology·2026
Same author

Meta-analysis of the effects of age at first calving on production outcomes, calving difficulty, and reproduction in dairy heifers.

Journal of dairy science·2026
Same author

Exploring diagnostic radiographers' experiences and understandings of informed consent and capacity assessment during general radiography imaging examinations of persons living with dementia: A qualitative interview study of UK practice.

Radiography (London, England : 1995)·2026
Same author

Safety, feasibility, and technical success of percutaneous cryoablation to treat vascular anomalies of the extremities.

Clinical radiology·2025
Same author

Safety and Feasibility of Endovascular Management of Pediatric Dialysis Access.

Cardiovascular and interventional radiology·2025
Same author

Suspected brodifacoum poisoning in tuatara (<i>Sphenodon punctatus</i>).

New Zealand veterinary journal·2025

Related Experiment Video

Updated: Jun 10, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Potential biomarkers for hypoxic-ischemic encephalopathy.

L Bennet1, L Booth, A J Gunn

  • 1Fetal Physiology and Neuroscience Group, Department of Physiology, University of Auckland, Private Bag 92019, Auckland, New Zealand. l.bennet@auckland.ac.nz

Seminars in Fetal & Neonatal Medicine
|July 22, 2010
PubMed
Summary
This summary is machine-generated.

Developing accurate biomarkers is crucial for identifying infants who can benefit from therapeutic hypothermia after birth-related hypoxia-ischemia (HI). Current biomarkers are often imprecise and lack utility during the critical treatment window.

More Related Videos

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Related Experiment Videos

Last Updated: Jun 10, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Area of Science:

  • Neonatal neurology
  • Biomarker research
  • Hypoxia-ischemia injury

Background:

  • Therapeutic hypothermia improves outcomes for infants with hypoxia-ischemia (HI).
  • Current enrollment criteria for hypothermia treatment are suboptimal, leading to undertreatment and overtreatment.
  • Improved biomarkers are needed to precisely identify infants who can benefit from intervention.

Purpose of the Study:

  • To critically evaluate the utility of proposed biomarkers for neonatal brain injury after HI.
  • To assess biomarkers against the 'window of opportunity' for effective treatment (up to 6-8 hours post-HI).
  • To identify limitations of current biomarkers in identifying treatable injury and predicting long-term outcomes.

Main Methods:

  • Review of experimental studies on biochemical, electronic monitoring, and imaging biomarkers.
  • Evaluation of biomarker precision and timing relative to the latent phase of HI injury.
  • Analysis of biomarker correlation with injury severity and long-term neurodevelopmental outcomes.

Main Results:

  • Most current biomarkers are most precise for severe injuries, which are already easily identified.
  • Biomarker correlation is strongest after the critical 'latent phase' when injury is no longer treatable.
  • Existing biomarkers have limited utility in identifying infants who can benefit from early intervention.

Conclusions:

  • There is a critical need for novel biomarkers that are precise during the treatable 'latent phase' of HI.
  • Accurate biomarkers are essential for optimizing therapeutic hypothermia enrollment and improving clinical trial design.
  • Further research is required to develop biomarkers that can accurately predict neurodevelopmental outcomes and guide treatment decisions in neonates with HI.